Search research articles
Contact Us
Filters
Showing results (11-20 of 77) with videos related to
Page
of 8
Sort By:
Revue Medicale De Liege
|
April 28, 2007
[Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes]
A J Scheen, L F Van Gaal
International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity
|
March 28, 2002
The importance of obesity in diabetes and its treatment with sibutramine
L F Van Gaal, F W Peiffer
Obesity Research
|
June 1, 2000
Overweight, obesity, and blood pressure: the effects of modest weight reduction
I L Mertens, L F Van Gaal
Revue Medicale De Liege
|
February 29, 2008
[Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system]
A J Scheen, L F Van Gaal
Revue Medicale De Liege
|
June 20, 2008
[Medication of the month... Exenatide (Byetta) incretinomimetic in the treatment of type 2 diabetes after failure and as add-on therapy to oral agents]
A J Scheen, L F Van Gaal
Revue Medicale De Liege
|
September 28, 2011
[Glycemic control before and after sitagliptin in general medical practice: analysis of determinant factors in the Belgian observational study "SUGAR"]
A J Scheen, L F Van Gaal
Revue Medicale De Liege
|
November 20, 2010
[Clinical study of the month. Accord-lipid and accord-eye: towards a new positioning of fenofibrate in the management of type 2 diabetes]
A J Scheen, L F Van Gaal
Revue Medicale De Liege
|
December 5, 2013
[Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation]
A J Scheen, L F Van Gaal
Diabetologia
|
March 26, 2003
Rationale and options for combination therapy in the treatment of Type 2 diabetes
L F Van Gaal, I H De Leeuw
The International Journal of Risk & Safety in Medicine
|
March 21, 2013
Human obesity: a medical assessment of health risks
L F Van Gaal, I H De Leeuw
Page
of 8
Search research articles
Search
Showing results (11-20 of 77) with videos related to
Sort By:
Page
of 8
Revue Medicale De Liege
|
April 28, 2007
[Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes]
A J Scheen, L F Van Gaal
International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity
|
March 28, 2002
The importance of obesity in diabetes and its treatment with sibutramine
L F Van Gaal, F W Peiffer
Obesity Research
|
June 1, 2000
Overweight, obesity, and blood pressure: the effects of modest weight reduction
I L Mertens, L F Van Gaal
Revue Medicale De Liege
|
February 29, 2008
[Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system]
A J Scheen, L F Van Gaal
Revue Medicale De Liege
|
June 20, 2008
[Medication of the month... Exenatide (Byetta) incretinomimetic in the treatment of type 2 diabetes after failure and as add-on therapy to oral agents]
A J Scheen, L F Van Gaal
Revue Medicale De Liege
|
September 28, 2011
[Glycemic control before and after sitagliptin in general medical practice: analysis of determinant factors in the Belgian observational study "SUGAR"]
A J Scheen, L F Van Gaal
Revue Medicale De Liege
|
November 20, 2010
[Clinical study of the month. Accord-lipid and accord-eye: towards a new positioning of fenofibrate in the management of type 2 diabetes]
A J Scheen, L F Van Gaal
Revue Medicale De Liege
|
December 5, 2013
[Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation]
A J Scheen, L F Van Gaal
Diabetologia
|
March 26, 2003
Rationale and options for combination therapy in the treatment of Type 2 diabetes
L F Van Gaal, I H De Leeuw
The International Journal of Risk & Safety in Medicine
|
March 21, 2013
Human obesity: a medical assessment of health risks
L F Van Gaal, I H De Leeuw
Page
of 8